Enliven Therapeutics, INC Form 4 insider transactions

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on May 1st and 2nd, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CEO, Samuel Kintz, executed sales of common stock on May 1st and 2nd, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares on April 28, 2025, according to a Form 4 filing with the SEC.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on April 21, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics CEO Samuel Kintz sold 5,000 shares of common stock at an average price of $16.4192, according to a Form 4 filing.

Anish Patel, COO of Enliven Therapeutics, sold shares of common stock on April 7, 2025, under a pre-arranged 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised options to acquire 1,000 shares of common stock at $2.48 and sold 1,000 shares at a weighted average price of $22.5045.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold 12,500 shares of common stock at an average price of $20.606 per share on March 19, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' CEO, Samuel Kintz, sold 12,500 shares of common stock at an average price of $20.8256, according to a Form 4 filing with the SEC.

Anish Patel, COO of Enliven Therapeutics, sold 6,667 shares of common stock at an average price of $21.4394, executed under a pre-arranged 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options for 10,000 shares at $2.48 on March 4, 2025, and reported a resulting change in beneficial ownership.

Benjamin Hohl, CFO of Enliven Therapeutics, executed options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Andrew John Phillips acquired stock options in Enliven Therapeutics, Inc. on February 6, 2025.

Director Lori Anne Kunkel reports the acquisition of stock options in Enliven Therapeutics, Inc.

Director Richard A. Heyman acquires stock options in Enliven Therapeutics, Inc.

Director Gupta Rishi acquired stock options in Enliven Therapeutics, Inc. on February 6, 2025.

Mika K Derynck, a director of Enliven Therapeutics, reported the acquisition of stock options on February 6, 2025.

Director Jake Bauer of Enliven Therapeutics acquired stock options exercisable for 20,491 shares of common stock.

Director Rahul D. Ballal of Enliven Therapeutics acquired stock options exercisable for 20,491 shares of common stock on February 6, 2025.

Anish Patel, Chief Operating Officer of Enliven Therapeutics, reports the sale of common stock and acquisition of stock options.

Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, acquired 171,000 stock options on February 6, 2025.

Enliven Therapeutics' CEO, Samuel Kintz, reports the acquisition of stock options for 490,000 shares on February 6, 2025.

Benjamin Hohl, CFO of Enliven Therapeutics, acquired 171,000 stock options on February 6, 2025, according to a Form 4 filing with the SEC.

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, acquired 171,000 stock options on February 6, 2025, according to a Form 4 filing.

Benjamin Hohl, CFO of Enliven Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics' Chief Operating Officer, Anish Patel, executed stock option exercises and sales of common stock on January 7, 2025, under a pre-arranged 10b5-1 trading plan.

Enliven Therapeutics' CFO, Benjamin Hohl, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl, CFO of Enliven Therapeutics, executed stock option exercises and sales on December 27 and December 30, 2024, according to a Form 4 filing.